J&J's $1.3 Bil. Inverness Buy Would End Royalty-Based Relationship
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's $1.3 bil. proposed acquisition of Inverness Medical Technology's diabetes care business builds on the firms' ongoing glucose meter and strip supply relationship begun in 1995.